000132789 001__ 132789
000132789 005__ 20240229105032.0
000132789 0247_ $$2doi$$a10.2147/CLEP.S155548
000132789 0247_ $$2pmid$$apmid:29670403
000132789 0247_ $$2pmc$$apmc:PMC5896664
000132789 037__ $$aDKFZ-2018-00433
000132789 041__ $$aeng
000132789 082__ $$a610
000132789 1001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b0$$eFirst author
000132789 245__ $$aVariation of diagnostic performance of fecal immunochemical testing for hemoglobin by sex and age: results from a large screening cohort.
000132789 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2018
000132789 3367_ $$2DRIVER$$aarticle
000132789 3367_ $$2DataCite$$aOutput Types/Journal article
000132789 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659531610_29253
000132789 3367_ $$2BibTeX$$aARTICLE
000132789 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132789 3367_ $$00$$2EndNote$$aJournal Article
000132789 520__ $$aFecal immunochemical tests (FITs) for hemoglobin in stool are increasingly used for colorectal cancer screening. Reported sensitivities and specificities have strongly varied between studies, but it is unclear to what extent such variation reflects differences between tests or between study population characteristics. We aimed to evaluate the key parameters of FIT performance for detecting advanced neoplasia (AN) according to sex and age.Sex- and age-specific sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs) for detecting AN of a quantitative FIT (FOB Gold®) were evaluated among 3211 men and women aged 50-79 years who underwent screening colonoscopy in Germany.At the cutoff recommended by the manufacturer (17 µg hemoglobin/g feces), sensitivity was higher (51.2% versus 34.7%, p=0.004) and specificity was lower (91.0% versus 94.8%, p<0.001) among 65-79 year-old participants compared with 50-64 year-old participants. PPVs and NPVs did not differ significantly between age groups. However, higher NPVs were observed among women compared with men (94.7% versus 92.5%, p=0.015). Specificity was also higher among women compared with men (94.7% versus 92.3%, p=0.007), while there was only a little variation in sensitivity (40.3% versus 41.8%, p=0.789) according to sex. In joint stratification by both factors, sensitivity ranged from 34.1% (95% CI 24.2%-45.2%) in 50-64 year-old women to 51.4% (95% CI 39.3%-63.3%) in 65-79 year-old men (p=0.029). The observed age and sex differences were highly consistent across a wide range of alternative cutoffs from 10 to 50 µg hemoglobin/g feces.There are major differences in diagnostic performance parameters according to sex and age, which should receive careful attention in the interpretation and comparison of results of FIT-based colorectal cancer screening studies.
000132789 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132789 588__ $$aDataset connected to CrossRef, PubMed,
000132789 7001_ $$0P:(DE-He78)f96b350b208db77bd493ed176dd66a83$$aQian, Jing$$b1
000132789 7001_ $$0P:(DE-He78)6c57e61dc44a62313e7075a0cefbb086$$aWerner, Simone$$b2$$eLast author$$udkfz
000132789 773__ $$0PERI:(DE-600)2494772-6$$a10.2147/CLEP.S155548$$gVol. 10, p. 381 - 389$$p381 - 389$$tClinical epidemiology$$v10$$x1179-1349$$y2018
000132789 909CO $$ooai:inrepo02.dkfz.de:132789$$pVDB
000132789 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132789 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f96b350b208db77bd493ed176dd66a83$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132789 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c57e61dc44a62313e7075a0cefbb086$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132789 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132789 9141_ $$y2018
000132789 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132789 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132789 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132789 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132789 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132789 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132789 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132789 980__ $$ajournal
000132789 980__ $$aVDB
000132789 980__ $$aI:(DE-He78)C070-20160331
000132789 980__ $$aI:(DE-He78)G110-20160331
000132789 980__ $$aI:(DE-He78)L101-20160331
000132789 980__ $$aUNRESTRICTED